Skip to main content
Top
Published in: BMC Psychiatry 1/2014

Open Access 01-12-2014 | Research article

Very low rates of screening for metabolic syndrome among patients with severe mental illness in Durban, South Africa

Authors: Shamima Saloojee, Jonathan K Burns, Ayesha A Motala

Published in: BMC Psychiatry | Issue 1/2014

Login to get access

Abstract

Background

Sub Saharan African is experiencing the largest increase in the prevalence of type 2 diabetes mellitus and cardiovascular disease globally. Metabolic syndrome (MetS) is a cluster of risk factors for these conditions. There is a consistently higher prevalence of cardiometabolic disease among individuals with severe mental illness (SMI) compared to the general population worldwide .However, it is known from research in high income countries that screening for MetS in patients with SMI is low. The objective of this study was to document the extent of the expected low frequency of testing for all the components of the metabolic syndrome (MetS) in patients with SMI in a low middle income country.

Methods

This was a cross sectional study, undertaken from January to June 2012 on out-patients with SMI who were treated with antipsychotic medication for at least 6 months. The study measured the proportion of participants who were tested for MetS in the previous year.

Results

The study included 331 (M: F; 167:164) participants with a mean age of 35.2 ± 11.98 years. The majority (78.8%) were black South Africans. Only 2 subjects (0.6%) were screened for all five components of MetS. Regarding the individual components, 99%, 0.6%, 3.9% and 1.8% were screened for raised blood pressure, abdominal obesity, hyperglycaemia, hypertriglyceridaemia and decreased high density lipoprotein cholesterol respectively.

Conclusion

It is unacceptable that less than one percent of our participants were adequately screened for modifiable risk factors for type 2 diabetes mellitus and cardiovascular disease which are the most common causes of mortality among patients with SMI. These results highlight the need for translating guidelines into action in low and middle income countries.
Literature
1.
go back to reference Mitchell AJ, Vancampfort D, Sweers K, Van Winkel R, Weiping Y, De Hert M: Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders. A systematic review and meta-analysis. Schizophr Bull. 2013, 39 (2): 306-318.CrossRefPubMed Mitchell AJ, Vancampfort D, Sweers K, Van Winkel R, Weiping Y, De Hert M: Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders. A systematic review and meta-analysis. Schizophr Bull. 2013, 39 (2): 306-318.CrossRefPubMed
2.
go back to reference Maaroganye K, Mohapi M, Kruger C, Rheeder P: The prevalence of metabolic syndrome and its associated factors in long -term patients in a specialist psychiatric hospital in South Africa. Afr J Psychiatry. 2013, 16: 414-423. Maaroganye K, Mohapi M, Kruger C, Rheeder P: The prevalence of metabolic syndrome and its associated factors in long -term patients in a specialist psychiatric hospital in South Africa. Afr J Psychiatry. 2013, 16: 414-423.
3.
go back to reference Parabiaghi A, Bonetto C, Ruggeri M, Lasalvia A, Leese M: Severe and persistent mental illness: a useful definition for prioritizing community-based mental health service interventions. Soc Psychiatry Psychiatr Epidemiol. 2006, 41: 457-463.CrossRefPubMed Parabiaghi A, Bonetto C, Ruggeri M, Lasalvia A, Leese M: Severe and persistent mental illness: a useful definition for prioritizing community-based mental health service interventions. Soc Psychiatry Psychiatr Epidemiol. 2006, 41: 457-463.CrossRefPubMed
4.
go back to reference Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645.CrossRefPubMed Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645.CrossRefPubMed
5.
go back to reference DeHert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S: Physical illness in patients with severe mental disorders I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011, 10: 52-77.CrossRef DeHert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S: Physical illness in patients with severe mental disorders I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011, 10: 52-77.CrossRef
6.
go back to reference Stahl SM, Mignon L, Meyer JM: Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr Scand. 2009, 119: 171-179.CrossRefPubMed Stahl SM, Mignon L, Meyer JM: Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr Scand. 2009, 119: 171-179.CrossRefPubMed
7.
go back to reference Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia : a systematic review and meta-analysis. Schizophr Res. 2010, 123: 225-233.CrossRefPubMedPubMedCentral Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia : a systematic review and meta-analysis. Schizophr Res. 2010, 123: 225-233.CrossRefPubMedPubMedCentral
8.
go back to reference De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, Van Winkel R, Mitchell AJ: Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011, 199: 99-105.CrossRefPubMed De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, Van Winkel R, Mitchell AJ: Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011, 199: 99-105.CrossRefPubMed
9.
go back to reference Clark M, Dubowski K, Colmore J: The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther. 1970, 11: 883-889.CrossRefPubMed Clark M, Dubowski K, Colmore J: The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther. 1970, 11: 883-889.CrossRefPubMed
10.
go back to reference Mitchell AJ, Dellafon D, Vancamfort D, Correll CU, DeHert M: Guideline concomitant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of monitoring practices. Psychol Med. 2012, 42 (01): 125-147.CrossRefPubMed Mitchell AJ, Dellafon D, Vancamfort D, Correll CU, DeHert M: Guideline concomitant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of monitoring practices. Psychol Med. 2012, 42 (01): 125-147.CrossRefPubMed
11.
go back to reference De Hert MA, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, Newcomer JW, Uwakwe R, Asai I, Möller H-J, Gautam S, Detraux J, Correll CU: Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011, 10 (2): 138-151.CrossRefPubMedPubMedCentral De Hert MA, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, Newcomer JW, Uwakwe R, Asai I, Möller H-J, Gautam S, Detraux J, Correll CU: Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011, 10 (2): 138-151.CrossRefPubMedPubMedCentral
12.
go back to reference Suppes T, McElroy S, Hirschfeld R: Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder, a survey of 500 US psychiatrists. Psychopharmacol Bull. 2007, 40: 22-37.PubMed Suppes T, McElroy S, Hirschfeld R: Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder, a survey of 500 US psychiatrists. Psychopharmacol Bull. 2007, 40: 22-37.PubMed
13.
go back to reference Davis S: Diabetogenic drugs: treating chronic conditions to minimize new onset diabetes. S Afr Pharm J. 2012, 79 (3): 24-26. Davis S: Diabetogenic drugs: treating chronic conditions to minimize new onset diabetes. S Afr Pharm J. 2012, 79 (3): 24-26.
14.
go back to reference Ludwick JJ, Oosthuizen PP: Screening for and monitoring of cardio -metabolic risk factors in outpatients with severe mental illness in a primary care setting. Afr J Psychiatry. 2009, 12: 287-292.CrossRef Ludwick JJ, Oosthuizen PP: Screening for and monitoring of cardio -metabolic risk factors in outpatients with severe mental illness in a primary care setting. Afr J Psychiatry. 2009, 12: 287-292.CrossRef
15.
go back to reference Marsay C, Szabo CP: Screening for metabolic syndrome-adherence to guidelines. Afr J Psychiatry. 2011, 14: 64-66. Marsay C, Szabo CP: Screening for metabolic syndrome-adherence to guidelines. Afr J Psychiatry. 2011, 14: 64-66.
16.
go back to reference Singh D, Berkman A, Bresnahan M: Seroprevalence and HIV –associated factors among adults with severe mental illness- a vulnerable population. S Afr Med J. 2009, 99: 523-527.PubMedPubMedCentral Singh D, Berkman A, Bresnahan M: Seroprevalence and HIV –associated factors among adults with severe mental illness- a vulnerable population. S Afr Med J. 2009, 99: 523-527.PubMedPubMedCentral
17.
go back to reference Khatana S, Kane J, Taveira T, Bauer M, Wu W: Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS One. 2011, 6: e19298-CrossRefPubMedPubMedCentral Khatana S, Kane J, Taveira T, Bauer M, Wu W: Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS One. 2011, 6: e19298-CrossRefPubMedPubMedCentral
18.
go back to reference Shi L, Ascher-Svanum H, Chiang Y, Zhao Y, Fonseca V, Winstead D: Predictors of metabolic monitoring among schizophrenia patients with a new episode of second - generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry. 2009, 9: 80-CrossRefPubMedPubMedCentral Shi L, Ascher-Svanum H, Chiang Y, Zhao Y, Fonseca V, Winstead D: Predictors of metabolic monitoring among schizophrenia patients with a new episode of second - generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry. 2009, 9: 80-CrossRefPubMedPubMedCentral
19.
go back to reference Mittal D, Chenghui L, Williams JS, Viverito K, Landes RD, Owen RR: Monitoring veterans for metabolic side effects when prescribing antipsychotics. Psych Services. 2013, 64 (1): 28-35.CrossRef Mittal D, Chenghui L, Williams JS, Viverito K, Landes RD, Owen RR: Monitoring veterans for metabolic side effects when prescribing antipsychotics. Psych Services. 2013, 64 (1): 28-35.CrossRef
20.
go back to reference Bobes J, Alegrı’a A, Saiz-Gonzalez M, Barber I, Pe’rez J, Saiz-Ruiz J: Change in psychiatrists attitudes towards the physical health of patients with Schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. Euro Psychiat. 2010, 26 (5): 305-312.CrossRef Bobes J, Alegrı’a A, Saiz-Gonzalez M, Barber I, Pe’rez J, Saiz-Ruiz J: Change in psychiatrists attitudes towards the physical health of patients with Schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. Euro Psychiat. 2010, 26 (5): 305-312.CrossRef
21.
go back to reference Gonzalez C, Ahammed N, Fisher R: Improving physical health monitoring for out patients on antipsychotic medication. Psychiatr Bull. 2010, 34: 91-94.CrossRef Gonzalez C, Ahammed N, Fisher R: Improving physical health monitoring for out patients on antipsychotic medication. Psychiatr Bull. 2010, 34: 91-94.CrossRef
22.
go back to reference Morrato EH, Druss B, Hartung D, Valuck RJ, Allen R, Campagna E, Newcomer J: Metabolic testing rates in 3 state Medicaid programmes after FDA warnings and ADA/APA recommendations for second –generation antipsychotic drugs. Arch Gen Psychiatry. 2010, 67 (1): 17-24.CrossRefPubMed Morrato EH, Druss B, Hartung D, Valuck RJ, Allen R, Campagna E, Newcomer J: Metabolic testing rates in 3 state Medicaid programmes after FDA warnings and ADA/APA recommendations for second –generation antipsychotic drugs. Arch Gen Psychiatry. 2010, 67 (1): 17-24.CrossRefPubMed
23.
go back to reference Haupt D, Rosenblatt L, Kim E, Baker R, Whitehead R, Newcomer J: Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second generation antipsychotic agents. Am J Psychiat. 2009, 166: 345-353.CrossRefPubMed Haupt D, Rosenblatt L, Kim E, Baker R, Whitehead R, Newcomer J: Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second generation antipsychotic agents. Am J Psychiat. 2009, 166: 345-353.CrossRefPubMed
24.
go back to reference Mackin P, Bishop D, Watkinson H: A prospective study of monitoring practices for metabolic disease in antipsychotic - treated community psychiatric patients. BMC Psychiatry. 2007, 25: 7-28. Mackin P, Bishop D, Watkinson H: A prospective study of monitoring practices for metabolic disease in antipsychotic - treated community psychiatric patients. BMC Psychiatry. 2007, 25: 7-28.
25.
go back to reference Nguyen D, Brakoulias V, Boyce P: An evaluation of monitoring practices in patients on second generation antipsychotics. Australas Psychiatry. 2009, 17: 295-299.CrossRefPubMed Nguyen D, Brakoulias V, Boyce P: An evaluation of monitoring practices in patients on second generation antipsychotics. Australas Psychiatry. 2009, 17: 295-299.CrossRefPubMed
26.
go back to reference Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA: Dyslipidaemia independent of body mass in antipsychotic treated patients under real-life conditions. J Clin Psychopharmacol. 2008, 28: 132-137.CrossRefPubMed Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA: Dyslipidaemia independent of body mass in antipsychotic treated patients under real-life conditions. J Clin Psychopharmacol. 2008, 28: 132-137.CrossRefPubMed
27.
go back to reference Gul M, Nihgam A, Broughton N: Clinical monitoring of patients on clozapine. J Pakistan Psychiatr Soc. 2006, 3: 90- Gul M, Nihgam A, Broughton N: Clinical monitoring of patients on clozapine. J Pakistan Psychiatr Soc. 2006, 3: 90-
28.
go back to reference Young Kim J, Hi Kim S, Jeong Cho : Socioeconomic Status in Association with Metabolic Syndrome and Coronary Heart Disease Risk. Korean J Fam Med. 2013, 34 (2): 131-138.CrossRef Young Kim J, Hi Kim S, Jeong Cho : Socioeconomic Status in Association with Metabolic Syndrome and Coronary Heart Disease Risk. Korean J Fam Med. 2013, 34 (2): 131-138.CrossRef
29.
go back to reference Joshi A, Mehta S, Grover A, Talati K, PuricelliPerin DM, Malhotra B: Knowledge, attitude, and practices of individuals to prevent and manage metabolic syndrome in an Indian setting. Diabetes Technol Ther. 2013, 15 (8): 644-653.CrossRefPubMed Joshi A, Mehta S, Grover A, Talati K, PuricelliPerin DM, Malhotra B: Knowledge, attitude, and practices of individuals to prevent and manage metabolic syndrome in an Indian setting. Diabetes Technol Ther. 2013, 15 (8): 644-653.CrossRefPubMed
30.
go back to reference Druss BG, Zhao I, Cummings JR, Shim RS, Rust GS, Marcus SC: Mental Comorbidity and Quality of Diabetes Care Under Medicaid: A 50-State Analysis. Med Care. 2012, 50 (5): 428-433.CrossRefPubMedPubMedCentral Druss BG, Zhao I, Cummings JR, Shim RS, Rust GS, Marcus SC: Mental Comorbidity and Quality of Diabetes Care Under Medicaid: A 50-State Analysis. Med Care. 2012, 50 (5): 428-433.CrossRefPubMedPubMedCentral
31.
go back to reference Schneiderhan ME, Batscha CL, Rosen C: Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy. 2009, 29 (8): 975-987.CrossRefPubMed Schneiderhan ME, Batscha CL, Rosen C: Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy. 2009, 29 (8): 975-987.CrossRefPubMed
32.
go back to reference Davis K: Emphasizing holistic care: A mental healthcare provider integrates physical healthcare into its services. Behav Healthc. 2009, 29 (3): 38-39.PubMed Davis K: Emphasizing holistic care: A mental healthcare provider integrates physical healthcare into its services. Behav Healthc. 2009, 29 (3): 38-39.PubMed
33.
go back to reference Keenan TE, Yu A, Cooper LA, Appel LJ, Guallar E, Gennusa JV, Dickerson FB, Crum RM, Anderson CA, Campbell LM, Young DR, Daumit GL: Racial patterns of cardiovascular disease risk factors in serious mental illness and the overall U.S. population. Schizophr Res. 2013, 15 (1): 211-216.CrossRef Keenan TE, Yu A, Cooper LA, Appel LJ, Guallar E, Gennusa JV, Dickerson FB, Crum RM, Anderson CA, Campbell LM, Young DR, Daumit GL: Racial patterns of cardiovascular disease risk factors in serious mental illness and the overall U.S. population. Schizophr Res. 2013, 15 (1): 211-216.CrossRef
34.
go back to reference Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380 (9859): 2095-2128.CrossRefPubMed Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380 (9859): 2095-2128.CrossRefPubMed
35.
go back to reference Motala AA, Pirie FJ, Esterhuizen T, Omar MAK: The prevalence of metabolic syndrome and determination of the optimal waist circumference cut off points in a rural South African community. Diabetes Care. 2011, 34 (4): 1032-1037.CrossRefPubMedPubMedCentral Motala AA, Pirie FJ, Esterhuizen T, Omar MAK: The prevalence of metabolic syndrome and determination of the optimal waist circumference cut off points in a rural South African community. Diabetes Care. 2011, 34 (4): 1032-1037.CrossRefPubMedPubMedCentral
Metadata
Title
Very low rates of screening for metabolic syndrome among patients with severe mental illness in Durban, South Africa
Authors
Shamima Saloojee
Jonathan K Burns
Ayesha A Motala
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2014
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-014-0228-5

Other articles of this Issue 1/2014

BMC Psychiatry 1/2014 Go to the issue